BioPharma DiveOriginal article
Novartis RNA drug falls short in rare muscle disease study
Data Readoutnegativedel-desiranNegative
AI Analysis
Summary
Novartis's RNA drug del-desiran failed to meet endpoints in a rare muscle disease study. The failure raises questions about the company's business development strategy given the $12 billion acquisition cost.
Clinical Trial Data
Primary Endpoint
Not Met
Outcome Details
RNA drug fell short in rare muscle disease study
Importance:7/10
Sentiment:
-0.80
clinical trial failureRNA therapyrare diseasedrug developmentacquisition
Related Companies
Read the original article
Published by BioPharma Dive on September 8, 2026 1:23 PM